Obecabtagene autoleucel: clinical use

Prescribing considerations

• Administration is restricted to qualified centres with clinicians experienced in haematological malignancy and CAR T-cell toxicity.
• Confirm autologous identity and full product traceability before administration.
• Reassess before treatment; delay where serious chemotherapy toxicity remains unresolved, severe intercurrent infection is present or graft-versus-host disease is active.
• Consider renal or hepatic impairment individually because clinical experience is lacking and complications may be less well tolerated.
• Evidence is limited in clinically relevant central nervous system disease.
• Consider the sodium, potassium and dimethyl sulfoxide content where clinically relevant.
• Provide the patient card and arrange long-term follow-up.

Contraindications and cautions

• Hypersensitivity to obecabtagene autoleucel or any excipient.
• Any applicable contraindication to the preparatory lymphodepleting chemotherapy must also be considered.

Monitoring

• Screen for HIV, hepatitis B, hepatitis C and other infectious agents before cell collection.
• Assess tumour burden and tumour-lysis risk before treatment.
• Monitor closely for cytokine release syndrome, neurotoxicity and other toxicities.
• Monitor full blood counts because cytopenias may be prolonged.
• Monitor for infection, viral reactivation, B-cell aplasia and hypogammaglobulinaemia; check immunoglobulins and manage infection risk appropriately.
• Monitor for tumour lysis syndrome, hypersensitivity and organ complications.
• Maintain lifelong vigilance for secondary malignancy.

Clinical pharmacology

A CD19-directed, genetically modified autologous T-cell therapy. Its chimeric receptor contains an anti-CD19 binding domain with 4-1BB co-stimulation and CD3-zeta signalling, producing T-cell activation, expansion and killing of CD19-expressing cells.

Formulation and product differences

• Patient-specific, colourless to pale-yellow, very opalescent dispersion for intravenous infusion.
• Supplied frozen in multiple infusion bags; bag fill volumes may differ according to the release certificate.
• Contains dimethyl sulfoxide, human albumin, sodium and potassium.
• Keep in the vapour phase of liquid nitrogen until preparation; thaw one bag at a time, administer promptly and do not refreeze.
• Do not use a leukodepleting filter.